Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Chembio Diagnostics stock | $5.5

Own Chembio Diagnostics stock in just a few minutes.

Fact checked

Chembio Diagnostics, Inc is a diagnostics & research business based in the US. Chembio Diagnostics shares (CEMI) are listed on the NASDAQ and all prices are listed in US Dollars. Chembio Diagnostics employs 324 staff and has a trailing 12-month revenue of around USD$29.1 million.

How to buy shares in Chembio Diagnostics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Chembio Diagnostics. Find the stock by name or ticker symbol: CEMI. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Chembio Diagnostics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$5.5, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Chembio Diagnostics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Chembio Diagnostics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Chembio Diagnostics share price

Use our graph to track the performance of CEMI stocks over time.

Chembio Diagnostics shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$5.5
52-week rangeUSD$2.25 - USD$15.89
50-day moving average USD$5.4368
200-day moving average USD$5.0352
Wall St. target priceUSD$9
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.73

Buy Chembio Diagnostics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Chembio Diagnostics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Chembio Diagnostics price performance over time

Historical closes compared with the close of $5.5 from 2020-12-18

1 week (2021-01-11) 3.38%
1 month (2020-12-18) 5.5
3 months (2020-10-16) 13.40%
6 months (2020-07-17) 10.00%
1 year (2020-01-17) 41.03%
2 years (2019-01-18) -21.99%
3 years (2018-01-18) 8.75
5 years (2016-01-15) 27.91%

Chembio Diagnostics financials

Revenue TTM USD$29.1 million
Gross profit TTM USD$3.5 million
Return on assets TTM -18.13%
Return on equity TTM -74.57%
Profit margin -76.55%
Book value $1.682
Market capitalisation USD$104.5 million

TTM: trailing 12 months

Shorting Chembio Diagnostics shares

There are currently 3.9 million Chembio Diagnostics shares held short by investors – that's known as Chembio Diagnostics's "short interest". This figure is 7.3% up from 3.6 million last month.

There are a few different ways that this level of interest in shorting Chembio Diagnostics shares can be evaluated.

Chembio Diagnostics's "short interest ratio" (SIR)

Chembio Diagnostics's "short interest ratio" (SIR) is the quantity of Chembio Diagnostics shares currently shorted divided by the average quantity of Chembio Diagnostics shares traded daily (recently around 2.4 million). Chembio Diagnostics's SIR currently stands at 1.6. In other words for every 100,000 Chembio Diagnostics shares traded daily on the market, roughly 1600 shares are currently held short.

However Chembio Diagnostics's short interest can also be evaluated against the total number of Chembio Diagnostics shares, or, against the total number of tradable Chembio Diagnostics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Chembio Diagnostics's short interest could be expressed as 0.19% of the outstanding shares (for every 100,000 Chembio Diagnostics shares in existence, roughly 190 shares are currently held short) or 0.1953% of the tradable shares (for every 100,000 tradable Chembio Diagnostics shares, roughly 195 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Chembio Diagnostics.

Find out more about how you can short Chembio Diagnostics stock.

Chembio Diagnostics share dividends

We're not expecting Chembio Diagnostics to pay a dividend over the next 12 months.

Have Chembio Diagnostics's shares ever split?

Chembio Diagnostics's shares were split on a 1:8 basis on 30 May 2012. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Chembio Diagnostics shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Chembio Diagnostics shares which in turn could have impacted Chembio Diagnostics's share price.

Chembio Diagnostics share price volatility

Over the last 12 months, Chembio Diagnostics's shares have ranged in value from as little as $2.25 up to $15.89. A popular way to gauge a stock's volatility is its "beta".

CEMI.US volatility(beta: 2.1)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Chembio Diagnostics's is 2.1024. This would suggest that Chembio Diagnostics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Chembio Diagnostics overview

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, Dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and Shire Human Genetic Therapies, Inc. to develop a novel POC diagnostic test. It also has a strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus, and IgM and IgG antibodies on the LumiraDx and Chembio DPP platforms. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site